Allergan Biocell Breast Implant Lawsuit

Allergan BIOCELL textured breast implants and tissue expanders were linked to a rare type of cancer known as breast implant-associated anaplastic large cell lymphoma or BIA-ALCL and have been recalled. Many people may be filing Allergan BIOCELL Breast Implant Lawsuits to seek compensation for their medical costs and other damages.

free case evaluation
A Summary
Allergan Biocell Breast Implant Lawsuit

In July of 2019, the FDA asked breast implant maker, Allergan to recall its BIOCELL textured breast implants due to an increased risk of a specific type of cancer known as breast implant-associated anaplastic large cell lymphoma or BIA-ALCL.

Implant recipients and their loved ones are filing Allergan Biocell Breast Implant Lawsuits to seek compensation for cancer treatments, medical costs and other damages. The company may be facing thousands of lawsuits for both medical injury product liability and class action causes.

Allergan Breast Implant Recall

Two years after a non-Hodgkin’s lymphoma type, BIA-ALCL was identified by the World Health Organization, in 2018 health authorities in Europe, Australia, Brazil and Israel suspended sales of Allergan textured breast implants. The company continued to sell their implants in the U.S. until July 2019 when analysis showed that Allergan implant risk of BIA-ALCL was six times higher than other products, the FDA requested that Allergan recall their BIOCELL textured breast implants.

The Allergan textured breast implant recall requested by the FDA included:

  • Allergan Natrelle Saline-Filled Breast Implants
  • Allergan Natrelle Silicone-Filled Textured Breast Implants
  • Allergan Natrelle 140 Highly Cohesive Anatomically Shaped Silicone Filled Breast Implants.

As part of the recall, the company agreed to pay for a portion of the implant cost but did not agree to surgical costs or medical costs associated with cancer concerns which has prompted some recipients to file lawsuits even if they have not been diagnosed with cancer. Allergan is also facing lawsuits filed by those who have been diagnosed with BIA-ALCL and seek compensation for injuries.

Allergan Biocell Breast Implant Lawsuit

Allergan Biocell Breast Implant Lawsuit

In cooperation with the U.S. Food and Drug Administration (FDA), breast implant maker and drug manufacturer, Allergan, issued a recall for Biocell breast implants in July 2019. The recall was requested by the FDA due to an increased risk of breast implant-associated cancer.

Implant recipients who have been diagnosed with BIA-ALCL are seeking compensation for their injuries and costs associated with cancer treatment. Others are seeking compensation for costs associated with reducing future risks.

Though Allergan did agree to and issued a voluntary recall of all Biocell textured breast implants and tissue expanders, the company has not agreed to help women with medical costs associated with troublesome devices and will only cover the cost of the implant itself.

Individuals who received the Biocell textured implants are filing lawsuits to seek compensation for medical costs including:

  • Cancer treatment
  • Lost wages
  • Pain and suffering
  • Surgical removal
  • Diagnostic testing
  • Medical monitoring

Allergan Biocell Breast Implant Recall

In 2016, the World Health Organization (WHO) recognized a specific type of cancer known as breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare form of non-Hodgkin’s lymphoma or T-cell lymphoma that develops and is located in the scar capsule surrounding the breast implant.

In December 2018, sales of Allergan textured breast implants were suspended in  Israel, Brazil, Australia and all 33 countries of the European Union. In May 2019, Allergan’s license for the Biocell breast implants was suspended in Canada but the company took no action in the U.S. until the FDA specifically requested that the implants be recalled in July 2019.

The FDA’s request as made after analysis showed the risk of BIA-ALCL with Allergan Biocell textured implants was 6 times higher than textured implants from other manufacturers.

The recall covers several styles of Allergan Biocell implants including:

  • Allergan Natrelle Saline-Filled Breast Implants
  • Allergan Natrelle Silicone-Filled Textured Breast Implants
  • Allergan Natrelle 140 Highly Cohesive Anatomically Shaped Silicone Filled Breast Implants.

The recall covers the cost of replacement implants but does not cover cost of the surgery required to replace the implants, cost of surgical removal, any medical or diagnostic testing, or medical monitoring. Women or individuals who received the implants are filing lawsuits seeking compensation for these medical costs.

Individuals or loved ones of those who were diagnosed with BIA-ALCL after having been implanted with an Allergan BIOCELL textured implant are filing lawsuit seeking compensation for injuries associated with their cancer or death of the loved one.

Breast Implant Cancer

Anaplastic large cell lymphoma (ALCL) is a type of non-Hodgkin’s lymphoma, also called a T-cell lymphoma because it causes the T cells to produce an excess protein known as anaplastic lymphoma kinase (ALK1) which increases the growth of certain cancer cells.

Textured breast implants may increase the risk for ALCL, possibly through inflammatory processes which occur in scar tissue formation to hold the implants in place. Experts also believe that bacterial contamination and family history may also increase the risk but the link to textured breast implants is so high, that it has been termed Breast Implant-Associated ALCL or BIA-ALCL.

Allergan implants have been associated with an increased risk of BIA-ALCL that is six times higher than textured implants manufactured by other companies. As of August 2019, at least 573 cases of BIA-ALCL had been reported to the FDA, including 33 deaths. The majority of the reports (84%) involved Allergan textured implants and 12 out of 13 deaths which the implant manufacturer could be identified were linked to Allergan implants.

If detected early enough, BIA-ALCL may be treatable by removal of the breast implant and the surrounding scar tissue but the disease may spread or metastasize to other areas of the body. The median time from breast implant placement to diagnosis with BIA-ALCL appears to be about 8 years and many people are having their implants removed preemptively.

Filing an Allergan Breast Implant Lawsuit

People who have been diagnosed or loved ones of those who died due to a BIA-ALCL diagnosis after breast implant may be eligible for compensation through a medical injury or wrongful death lawsuit.

Patients who received an Allergan Biocell textured breast implant or tissue expander may be eligible for participation in a class action lawsuit which is seeking compensation for costs associated with the July 2019 recall.

The lawsuits are seeking compensation for:

  • Costs associated with surgical removal of the implant
  • Medical and diagnostic testing and monitoring

Each case is unique and must be evaluated separately but anyone who has been affected by the Allergan BIOCELL textured breast implant recall or cancer link should seek legal assistance.

Have you been affected by a drug or device listed?